Онкопедиатрия. 2017; 4: 294-300
Молекулярные подходы в диагностике пигментных новообразований кожи у детей: описание четырех случаев
https://doi.org/10.15690/onco.v4i4.1816Аннотация
В ходе традиционного морфологического анализа при дифференциальной диагностике между пигментным невусом и меланомой кожи нередко возникают затруднения. Использование молекулярных маркеров в дополнение к классическому гистологическому исследованию может способствовать минимизации этих затруднений при постановке правильного диагноза. В настоящей работе на образцах пигментных новообразований кожи от 4 детей в возрасте от 3 мес до 12 лет была проведена проверка информативности иммуногистохимического (ИГХ) анализа ряда белков в качестве маркеров при первичной диагностике меланомы кожи у педиатрических больных. Выявлены различия между меланомой и пигментными невусами. По результатам проведенного исследования, ИГХ-тест на изученные белки может рассматриваться как адекватный подход для первичной диагностики меланомы кожи у этой категории больных.
Список литературы
1. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83(7):825–846. doi: 10.4065/83.7.825.
2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51–65. doi: 10.1056/NEJMra052166.
3. Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol. 2009;27(6):529– 536. doi: 10.1016/j.clindermatol.2008.09.011.
4. Мень Т.Х., Дорошенко М.Б., Алиев М.Д. Злокачественная меланома кожи у детей и подростков в России: популяционное эпидемиологическое исследование // Саркомы костей, мягких тканей и опухоли кожи. — 2011. — №2 — С. 55–60. [Men TKh, Doroshenko MB, Aliev MD. Cutaneous malignant melanoma in children and adolescents in russia: population-based epidemiological study. Bone and soft tissue sarcomas and tumors of the skin. 2011;(2):55–60. (In Russ).]
5. Мень Т.Х., Рыков М.Ю., Поляков В.Г. Злокачественные новообразования у детей в России: основные показатели и тенденции // Российский онкологический журнал. — 2015. — Т. 20. — №2 — С. 43–47. [Men’ TKh, Rykov MYu, Polyakov VG. Malignancies in children in Russia: trends and highlights. Russian journal of oncology. 2015;20(2):43–47. (In Russ).]
6. Вишневская Я.В., Машенкина Я.А., Сендерович А.И., и др. Современная морфологическая, иммуногистохимическая и молекулярно-генетическая диагностика меланомы кожи // Вестник Московского Онкологического Общества. — 2011. — №9 — С. 2–4. [Vishnevskaya JaВ, Mashenkina YaA, Senderovich AI, et al. Current status in pathology, immunohistochemistry, molecular-genetic aspects of melanoma. Proceedings of the Moscow Cancer Society. 2011;(9):2–4. (In Russ).]
7. Wechsler J, Bastuji-Garin S, Spatz A, et al. Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol. 2002;138(5):625–628. doi: 10.1001/archderm.138.5.625.
8. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Annu Rev Pathol. 2014;9:239–271. doi: 10.1146/annurev-pathol-012513-104658.
9. Livestro DP, Kaine EM, Michaelson JS, et al. Melanoma in the young: differences and similarities with adult melanoma — a case-matched controlled analysis. Cancer. 2007;110(3):614–624. doi: 10.1002/cncr.22818.
10. Averbook BJ, Lee SJ, Delman KA, et al. Pediatric melanoma: analysis of an international registry. Cancer. 2013;119(22):4012–4019. doi: 10.1002/cncr.28289.
11. Давыдов М.М., Аксель Е.М. Стандартизованные показатели онкоэпидемиологической ситуации 2015 г. // Евразийский онкологический журнал. — 2017. — Т. 5. — №2 — С. 298–317. [Davydov MM, Aksel’ EM. Standardized indicators of the oncological epidemiological situation in 2015. Eurasian journal of oncology. 2017;5(2):298– 317. (In Russ).]
12. Волгарева Г.М., Лебедева А.В., Поляков В.Г. Пигментные новообразования кожи у детей и подростков: в поисках диагностических маркеров меланомы кожи // Онкопедиатрия. — 2016. — Т. 3. — №1 — С. 16–23. [Volgareva GM, Lebedeva AV, Polyakov VG. Pigment cell skin neoplasms in children and adolescents: searching skin melanoma diagnostic markers. Oncopediatrics. 2016;3(1):16–23. (In Russ).]. doi: 10.15690/nco.v3i1.1525.
13. Барышников А.Ю., Тоневицкий А.Г. Моноклональные антитела в лаборатории и клинике. — М.: Медицина; 1997. — С. 110–112. [Baryshnikov AYu, Tonevitskii AG. Monoklonal’nye antitela v laboratorii i klinike. Moscow: Meditsina; 1997. pp. 110–112. (In Russ).]
14. Рязанцева А.А., Завалишина Л.Э., Андреева Ю.Ю., Франк Г.А. Молекулярно- биологические подходы к дифференциальной диагностике меланомы кожи // Архив патологии. — 2009. — Т. 71. — №5 — С. 23–27. [Ryazantseva AA, Zavalishina LE, Andreeva YuYu, Frank GA. Molekulyarno-biologicheskie podkhody k differentsial’noi diagnostike melanomy kozhi. Arkh Patol. 2009;71(5):23–27. (In Russ).]
15. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–707. doi: 10.1038/366704a0.
16. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–1512. doi: 10.1101/gad.13.12.1501.
17. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576(1–2):22– 38. doi: 10.1016/j.mrfmmm.2004.08.021.
18. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer. 2006;95(4):496– 505. doi: 10.1038/sj.bjc.6603283.
19. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–190. doi: 10.1016/S0968-0004(00)89005-2.
20. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58(10):2170–2175.
21. Gerami P, Jewell SS, Pouryazdanparast P, et al. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn. 2011;13(3):352–358. doi: 10.1016/j.jmoldx.2011.01.011.
22. Oba J, Nakahara T, Abe T, et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 2011;62(2):116–123. doi: 10.1016/j.jdermsci.2011.02.011.
23. Garrido F, Cabrera T, Aptsiauri N. «Hard» and «soft» lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010;127(2):249– 256. doi: 10.1002/ijc.25270.
24. del Campo AB, Kyte JA, Carretero J, et al. Immune escape of cancer cells with beta2- microglobulin loss over the course of metastatic melanoma. Int J Cancer. 2014;134(1):102– 113. doi: 10.1002/ijc.28338.
25. Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol. 2011;33(4):321–334. doi: 10.1007/s00281-011-0270-z.
26. Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon- mediated rejection genes. Int J Cancer. 2012;131(2):387–395. doi: 10.1002/ijc.26471.
27. Ruiter DJ, Bhan AK, Harrist TJ, et al. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol. 1982;129(6):2808–2815.
Oncopediatrics. 2017; 4: 294-300
Molecular Approaches for the Diagnostics of Pediatric Pigment Skin Malformations: Four Cases
https://doi.org/10.15690/onco.v4i4.1816Abstract
Some difficulties are rather common in the course of traditional morphologic study when differential identification between pigment nevus and skin melanoma is conducted. To minimize these difficulties traditional histological examination can be supplemented with application of molecular markers. In the present study, the samples of pigmented skin lesions were used to assess the informative value of immunohistochemical (IHC) analysis of a number of proteins as markers in the primary diagnosis of skin melanoma in pediatric patients. Specimens of pigment skin malformations from four children aged from 3 months up to 12 years were studied. Dissimilarities were determined between melanoma and skin nevi. According to the obtained results of the conducted research, IHC-test for identified proteins can be considered as a suitable approach for primary diagnostics of skin melanoma in this category of patients.
References
1. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83(7):825–846. doi: 10.4065/83.7.825.
2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51–65. doi: 10.1056/NEJMra052166.
3. Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol. 2009;27(6):529– 536. doi: 10.1016/j.clindermatol.2008.09.011.
4. Men' T.Kh., Doroshenko M.B., Aliev M.D. Zlokachestvennaya melanoma kozhi u detei i podrostkov v Rossii: populyatsionnoe epidemiologicheskoe issledovanie // Sarkomy kostei, myagkikh tkanei i opukholi kozhi. — 2011. — №2 — S. 55–60. [Men TKh, Doroshenko MB, Aliev MD. Cutaneous malignant melanoma in children and adolescents in russia: population-based epidemiological study. Bone and soft tissue sarcomas and tumors of the skin. 2011;(2):55–60. (In Russ).]
5. Men' T.Kh., Rykov M.Yu., Polyakov V.G. Zlokachestvennye novoobrazovaniya u detei v Rossii: osnovnye pokazateli i tendentsii // Rossiiskii onkologicheskii zhurnal. — 2015. — T. 20. — №2 — S. 43–47. [Men’ TKh, Rykov MYu, Polyakov VG. Malignancies in children in Russia: trends and highlights. Russian journal of oncology. 2015;20(2):43–47. (In Russ).]
6. Vishnevskaya Ya.V., Mashenkina Ya.A., Senderovich A.I., i dr. Sovremennaya morfologicheskaya, immunogistokhimicheskaya i molekulyarno-geneticheskaya diagnostika melanomy kozhi // Vestnik Moskovskogo Onkologicheskogo Obshchestva. — 2011. — №9 — S. 2–4. [Vishnevskaya JaV, Mashenkina YaA, Senderovich AI, et al. Current status in pathology, immunohistochemistry, molecular-genetic aspects of melanoma. Proceedings of the Moscow Cancer Society. 2011;(9):2–4. (In Russ).]
7. Wechsler J, Bastuji-Garin S, Spatz A, et al. Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol. 2002;138(5):625–628. doi: 10.1001/archderm.138.5.625.
8. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Annu Rev Pathol. 2014;9:239–271. doi: 10.1146/annurev-pathol-012513-104658.
9. Livestro DP, Kaine EM, Michaelson JS, et al. Melanoma in the young: differences and similarities with adult melanoma — a case-matched controlled analysis. Cancer. 2007;110(3):614–624. doi: 10.1002/cncr.22818.
10. Averbook BJ, Lee SJ, Delman KA, et al. Pediatric melanoma: analysis of an international registry. Cancer. 2013;119(22):4012–4019. doi: 10.1002/cncr.28289.
11. Davydov M.M., Aksel' E.M. Standartizovannye pokazateli onkoepidemiologicheskoi situatsii 2015 g. // Evraziiskii onkologicheskii zhurnal. — 2017. — T. 5. — №2 — S. 298–317. [Davydov MM, Aksel’ EM. Standardized indicators of the oncological epidemiological situation in 2015. Eurasian journal of oncology. 2017;5(2):298– 317. (In Russ).]
12. Volgareva G.M., Lebedeva A.V., Polyakov V.G. Pigmentnye novoobrazovaniya kozhi u detei i podrostkov: v poiskakh diagnosticheskikh markerov melanomy kozhi // Onkopediatriya. — 2016. — T. 3. — №1 — S. 16–23. [Volgareva GM, Lebedeva AV, Polyakov VG. Pigment cell skin neoplasms in children and adolescents: searching skin melanoma diagnostic markers. Oncopediatrics. 2016;3(1):16–23. (In Russ).]. doi: 10.15690/nco.v3i1.1525.
13. Baryshnikov A.Yu., Tonevitskii A.G. Monoklonal'nye antitela v laboratorii i klinike. — M.: Meditsina; 1997. — S. 110–112. [Baryshnikov AYu, Tonevitskii AG. Monoklonal’nye antitela v laboratorii i klinike. Moscow: Meditsina; 1997. pp. 110–112. (In Russ).]
14. Ryazantseva A.A., Zavalishina L.E., Andreeva Yu.Yu., Frank G.A. Molekulyarno- biologicheskie podkhody k differentsial'noi diagnostike melanomy kozhi // Arkhiv patologii. — 2009. — T. 71. — №5 — S. 23–27. [Ryazantseva AA, Zavalishina LE, Andreeva YuYu, Frank GA. Molekulyarno-biologicheskie podkhody k differentsial’noi diagnostike melanomy kozhi. Arkh Patol. 2009;71(5):23–27. (In Russ).]
15. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–707. doi: 10.1038/366704a0.
16. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–1512. doi: 10.1101/gad.13.12.1501.
17. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576(1–2):22– 38. doi: 10.1016/j.mrfmmm.2004.08.021.
18. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer. 2006;95(4):496– 505. doi: 10.1038/sj.bjc.6603283.
19. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–190. doi: 10.1016/S0968-0004(00)89005-2.
20. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58(10):2170–2175.
21. Gerami P, Jewell SS, Pouryazdanparast P, et al. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn. 2011;13(3):352–358. doi: 10.1016/j.jmoldx.2011.01.011.
22. Oba J, Nakahara T, Abe T, et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 2011;62(2):116–123. doi: 10.1016/j.jdermsci.2011.02.011.
23. Garrido F, Cabrera T, Aptsiauri N. «Hard» and «soft» lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010;127(2):249– 256. doi: 10.1002/ijc.25270.
24. del Campo AB, Kyte JA, Carretero J, et al. Immune escape of cancer cells with beta2- microglobulin loss over the course of metastatic melanoma. Int J Cancer. 2014;134(1):102– 113. doi: 10.1002/ijc.28338.
25. Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol. 2011;33(4):321–334. doi: 10.1007/s00281-011-0270-z.
26. Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon- mediated rejection genes. Int J Cancer. 2012;131(2):387–395. doi: 10.1002/ijc.26471.
27. Ruiter DJ, Bhan AK, Harrist TJ, et al. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol. 1982;129(6):2808–2815.
